Rocket Pharmaceuticals
Develops gene therapies for rare immune and cardiovascular disorders.
$3.82
After-hours close−0.04 (−0.91%)
At close$3.86(+6.49%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 92.01%Insiders 21.22%
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 109.19M · Float 86.96M · 79.6% free float
Institutions13F, as of Jun 30, 2026
185 holders · 100.46M shares · 19 new positions · 90 increased · 65 reduced · 37 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 17.69M | 16.20% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 9.92M | 9.09% | +2.09M | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 5.81M | 5.32% | +1.12M | Aug 13, 2026 |
| Citigroup Inc | 4.87M | 4.46% | −242.2K | Aug 3, 2026 |
| Marshall Wace, LLP | 4.03M | 3.69% | +990.5K | Aug 13, 2026 |
| Millennium Management LLC | 4.00M | 3.66% | +882.2K | Aug 14, 2026 |
| Newtyn Management, LLC | 4.00M | 3.66% | +834.1K | Aug 14, 2026 |
| Maverick Capital Ltd | 3.92M | 3.59% | +356.6K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Vanguard Portfolio Management | 5.35% | 5.85M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| RTW Investments, LP | director, 10 percent owner, other: See remarks | 18.19M | 16.66% | Sep 23, 2025 |
| Gaurav Shah | officer: CEO | 1.06M | 0.97% | Aug 20, 2026 |
| Martin Wilson | officer: General Counsel | 673.9K | 0.62% | Aug 20, 2026 |
| Christopher James Stevens | officer: Chief Operating Officer | 505.8K | 0.46% | Aug 13, 2026 |
| Kinnari Patel | officer: See Remarks | 468.7K | 0.43% | May 22, 2025 |
| Syed Ali-aamir Rizvi | officer: Chief Medical Officer | 407.9K | 0.37% | Feb 13, 2026 |
| Gotham Makker | director | 395.9K | 0.36% | Jul 18, 2025 |
| Jonathan David Schwartz | officer: See Remarks | 299.1K | 0.27% | Nov 20, 2025 |
| Sarbani Chaudhuri | officer: See Remarks | 262.8K | 0.24% | Aug 13, 2026 |
| David P. Southwell | director | 204.5K | 0.19% | Aug 5, 2026 |
6 ten-percent owners hold 2.88M shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (592.7K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Martin Wilsonofficer: General Counsel | Sale | 631 | $3.38 | 673,853 |
| Aug 18, 2026 | Gaurav Shahofficer: CEO | Sale | 2,293 | $3.38 | 1,056,594 |
| Aug 13, 2026 | Gaurav Shahofficer: CEO | Sale | 2,837 | $3.38 | 1,058,887 |
| Aug 13, 2026 | Martin Wilsonofficer: General Counsel | Sale | 3,493 | $3.38 | 674,484 |
| Aug 11, 2026 | Sarbani Chaudhuriofficer: See Remarks | Sale | 4,701 | $3.50 | 262,809 |
| Aug 11, 2026 | Christopher James Stevensofficer: Chief Operating Officer | Sale | 36,658 | $3.50 | 505,784 |
| May 21, 2026 | Gaurav Shahofficer: CEO | Sale | 55,684 | $3.09 | 1,061,724 |
| May 19, 2026 | John Militelloofficer: See Remarks | Sale | 384 | $3.01 | 89,780 |
| May 19, 2026 | Martin Wilsonofficer: General Counsel | Sale | 662 | $3.01 | 677,977 |
| May 19, 2026 | Gaurav Shahofficer: CEO | Sale | 2,409 | $3.01 | 1,040,918 |
CongressHouse and Senate disclosures
Not reported.